Phase 1 Single Dose Open Label Study To Investigate The Potential DDI Between PF-00299804 And Paroxetine In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2015
At a glance
- Drugs Dacomitinib; Moxifloxacin; Paroxetine
- Indications Affective disorders; Anxiety disorders; Cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 21 Jun 2012 Actual end date changed from (Jul 2011) to (Jun 2011) added as reported by ClinicalTrials.gov.
- 22 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.